Clinical trials
Phase 4 Vomiting trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
99 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 5 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 7 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
| Unknown status | 15 |
| Terminated | 10 |
| Recruiting | 6 |
| Not yet recruiting | 5 |
| Withdrawn | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 6 |
| Assiut University | 4 |
| Yonsei University | 3 |
| Dr. Stephen Freedman | 2 |
| LG Life Sciences | 2 |
| Radboud University Medical Center | 2 |
| Rutgers, The State University of New Jersey | 2 |
| University of Pittsburgh | 2 |
| Weill Medical College of Cornell University | 2 |
| Aga Khan University Hospital, Pakistan | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vomiting | 99 |
| Nausea | 62 |
| Postoperative Nausea and Vomiting | 17 |
| Neoplasms | 7 |
| Postoperative Pain | 7 |
| Pain | 6 |
| Pruritus | 5 |
| Constipation | 3 |
| Abdominal Pain | 2 |
| Agnosia | 2 |
Trials
Showing 51 to 75 of 99. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.